jetcityimage/iStock Editorial via Getty Images
- An expert panel of the EU drug regulator has endorsed marketing authorization for Eli Lilly’s (LLY) weight loss pill, Foundayo (orforglipron), paving the way for its approval in a market where rival Novo (NVO) holds the first-mover advantage.
- During its
